Choice of prosthetic heart valves:update for the next generation.
Intervention for valvular heart disease poses unique clinical challenges in cardiology because the diseases are of relatively low prevalence, the interventions do not lend themselves to randomized comparative trials, and important clinical end points are assessed only after decades of follow-up. In addition, continuing advances in prosthetic heart valve technology make follow-up a moving target because long-term data by definition are available only for older prostheses. Newer tissue and mechanical prostheses afford superior hemodynamics compared with their older counterparts, and data suggest that durability and patient mortality are superior with newer compared with older bioprostheses. Arbitrary cutoffs dictating valve choice based predominantly on patient age may not give appropriate weight to individual patient perspectives. In educating and counseling patients regarding choices in heart valve prostheses, the clinician should help the patient weigh the relative merits for the individual patient of projected mortality, valve durability, and requirement for anticoagulation, with associated freedom from re-operation, hemorrhagic and thromboembolic risk, and impact on lifestyle.